DNMT3L

DNA (cytosine-5)-methyltransferase 3-like · Q9UJW3 · DNMT3L on Sugi Atlas →

5,415 patent compounds predicted against DNMT3L, 4,295 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL1878590)	0.98	6/20
Hydrochloric Acid (SCHEMBL1880578)	0.98	6/20
Hydrochloric Acid (SCHEMBL1880676)	0.98	6/20
Hydrochloric Acid (SCHEMBL1886043)	0.98	6/20
Hydrochloric Acid (SCHEMBL1885682)	0.83	6/20
Hydrochloric Acid (SCHEMBL1886886)	0.83	6/20
Hydrochloric Acid (SCHEMBL1881343)	0.82	6/20
Hydrochloric Acid (SCHEMBL1884842)	0.82	6/20
Hydrochloric Acid (SCHEMBL1884452)	0.81	6/20
Hydrochloric Acid (SCHEMBL1877710)	0.80	6/20
Hydrochloric Acid (SCHEMBL1887698)	0.80	6/20
Hydrochloric Acid (SCHEMBL1888861)	0.80	6/20
SCHEMBL1884952	0.78	6/20
Hydrochloric Acid (SCHEMBL1884368)	0.78	6/20
Hydrochloric Acid (SCHEMBL1884373)	0.75	6/20
Hydrochloric Acid (SCHEMBL1882623)	0.75	6/20
Hydrochloric Acid (SCHEMBL1884918)	0.75	6/20
Hydrochloric Acid (SCHEMBL1887976)	0.75	6/20
Hydrochloric Acid (SCHEMBL1883417)	0.72	6/20
Hydrochloric Acid (SCHEMBL1887308)	0.72	6/20

Clinical trials — most relevant to DNMT3L by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC	PHASE3	UNKNOWN
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)	PHASE2/PHASE3	COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)	PHASE2	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)	PHASE1	RECRUITING
DNA Methylation and Perioperative Pain Treatment	nan	COMPLETED
Effect of DNMT SNPs on DNA Methylation in Primary ITP	nan	UNKNOWN
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)	nan	COMPLETED
Analysis of DNA Methylation in Spondyloarthritis	nan	COMPLETED
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL	nan	RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Family Resilience Initiative Research Program	nan	UNKNOWN
Genetic Study of Familial Factors in Patients With Colon Cancer	nan	COMPLETED
Exploratory Study of Rectal Mucus for Diagnosing Disease	nan	COMPLETED
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Characterization of Methylation Pattern in Human Germ Cells of Patients Undergoing ICSI Treatment	nan	COMPLETED
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD	nan	NOT_YET_RECRUITING
Characterization and Contribution of Genome-wide DNA Methylation (DNA Methylation Episignatures) in Rare Diseases With Prenatal Onset	nan	RECRUITING
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING
Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C	nan	UNKNOWN
Diagnosis of Colorectal Cancer and Advanced Adenoma Using Cancer-specific Methylation Signatures	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a DNMT3L binder may also engage these)

Protein	Name	Similarity
Q1LZ50	—	0.988	Q1LZ50 →
Q9CWR8	—	0.985	Q9CWR8 →
Q6DCD7	—	0.978	Q6DCD7 →
O88509	—	0.976	O88509 →
F1ND48	—	0.973	F1ND48 →
Q4KLT3	—	0.972	Q4KLT3 →
Q66IH9	—	0.972	Q66IH9 →
Q7TPQ3	—	0.972	Q7TPQ3 →
O94952	—	0.971	O94952 →
Q9BXT6	—	0.971	Q9BXT6 →
A0A0R4IMY7	—	0.971	A0A0R4IMY7 →
Q8CAE2	—	0.970	Q8CAE2 →
Q99MV5	—	0.970	Q99MV5 →
Q5T8I9	—	0.970	Q5T8I9 →
E1BVR9	—	0.970	E1BVR9 →
Q8N1G2	—	0.970	Q8N1G2 →
Q6NX27	—	0.970	Q6NX27 →
DNMT3B	DNA (cytosine-5)-methyltransferase 3B	0.970	landscape →
Q5U2Z5	—	0.969	Q5U2Z5 →
Q90678	—	0.969	Q90678 →
F4IVI0	—	0.969	F4IVI0 →
P47823	—	0.969	P47823 →
Q5RL51	—	0.969	Q5RL51 →
Q5R981	—	0.969	Q5R981 →
Q3ZBT2	—	0.969	Q3ZBT2 →
Q4R3W5	—	0.969	Q4R3W5 →
Q32PY6	—	0.969	Q32PY6 →
Q7Z7L1	—	0.969	Q7Z7L1 →
Q3U2U7	—	0.969	Q3U2U7 →
A0JPF9	—	0.969	A0JPF9 →